Dimethyltryptamine

BEDFORD, Mass. & DAVIS, Calif.--(BUSINESS WIRE)--Delix Therapeutics, a clinical‑stage neuroscience company developing non‑hallucinogenic neuroplastogens for the treatment of serious neuropsychiatric and neurodegenerative disorders, announced that the peer‑reviewed manuscript “Zalsupindole is a non‑dissociative, non‑hallucinogenic neuroplastogen with therapeutic effects comparable to ketamine and psychedelics” has been published in ACS Chemical Neuroscience. The in‑depth study, authored by Delix scientists and co-founder David E. Olson, PhD, provides additional pharmacological profiling and mechanistic details about Delix’s lead candidate zalsupindole (DLX‑001). This first‑in‑class analog of 5‑MeO‑DMT produces robust structural and functional neuroplasticity without the hallucinogenic, psychotomimetic, or dissociative effects associated with first‑generation psychoplastogens. In preclinical assays, zalsupindole promoted cortical neuritogenesis in vitro, increased dendritic spine density in vivo, and enhanced measures of functional plasticity to a similar or greater extent than ketamine, psilocybin and DMT. Pharmacokinetic studies revealed that zalsupindole is highly brain‑penetrant, distributes rapidly, and is cleared quickly. Receptor profiling demonstrated that zalsupindole is a low‑potency partial agonist at 5‑HT₂A/C receptors and exhibits high selectivity for serotonergic targets while antagonizing 5‑HT₂B receptors. These characteristics contribute to its robust neuroplasticity‑promoting effects and support a favorable cardiovascular safety profile as has been seen in clinical studies. “At Delix, we believe that promoting neuroplasticity to repair dysfunctional neural circuits is the key to treating a broad range of neuropsychiatric conditions,” said David E. Olson, PhD, co‑founder and Chief Innovation Officer of Delix Therapeutics. “By systematically comparing zalsupindole with clinically effective, first-generation psychoplastogens such as ketamine, psilocybin, and DMT, we have shown that our compound produces the same rapid and sustained structural and functional plasticity without inducing hallucinations or dissociation. The data described in this paper provide a clear path toward developing safe, effective, and scalable neuroplastogen therapeutics for people who need them.” Delix’s neuroplasticity platform has generated thousands of non‑hallucinogenic plasticity‑promoting compounds. The publication follows encouraging clinical results: in a Phase 1 study in healthy volunteers, zalsupindole demonstrated a favorable safety and tolerability profile with no serious adverse events or psychotomimetic, hallucinatory or dissociative effects while EEG biomarkers demonstrated CNS exposure and activity relevant to neuroplasticity. Delix is currently completing a Phase 1b study in patients with major depressive disorder (MDD). “Delix is honored that ACS Chemical Neuroscience has chosen to publish this important characterization of the first novel neuroplastogen to advance to the clinic and patients,” said Mark Rus, CEO of Delix Therapeutics. “By deepening our understanding of neuroplasticity, the serotonergic system, and sharing that with the field, we are driving forward the evidence that non‑hallucinogenic neuroplastogens can provide the robust rapid efficacy of psychedelics and other first generation plastogens, but at a completely different scale.” In addition to this ACS Chemical Neuroscience publication, Delix's research has been widely published in scientific journals including Science, Cell, Nature, Molecular Psychiatry, Frontiers in Psychiatry, and the Journal of Medicinal Chemistry, among others. The Company was also recognized in Chemical & Engineering News' Top 10 Start-ups to Watch, named to Nature Biotechnology's list of leading spinouts, and included in Fierce Biotech's prestigious "Fierce 15" list. About Zalsupindole (DLX‑001) Zalsupindole (DLX-001) is a novel, non‑hallucinogenic, non-dissociative isotryptamine neuroplastogen currently being evaluated for the treatment of Major Depressive Disorder (MDD). Preclinical data has demonstrated that DLX-001 increases dendritic spine density on neurons in the prefrontal cortex and has rapid and enduring antidepressant-like effects in animal models after a single dose. Recent Phase 1 data has demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. Delix is completing a Phase 1b study in MDD patients. About Neuroplastogens Neuroplastogens are a novel class of potentially disease-modifying therapeutics for psychiatric and neurological conditions. These compounds promote rapid and sustained neuroplasticity in select neural circuits resulting in fast-acting therapeutic effects. Neuroplastogens are novel chemical entities inspired by compounds that are proving to be beneficial across a range of therapeutic areas including mood, anxiety, cognitive, and neurodegenerative disorders in addition to other synaptopathies. Leveraging our deep mechanistic understanding and unique drug discovery engine to generate distinct compounds, Delix seeks to bring to market a pipeline of neuroplastogens that aim to be the faster, stronger, and more effective medicines of the future. About Delix Therapeutics Delix Therapeutics is a clinical-stage neuroscience company focused on harnessing the power of novel neuroplasticity‑promoting therapeutics to better treat patients struggling with difficult- to-treat neuropsychiatric and neurological disorders. The company's compounds are easily manufactured small molecules capable of rapidly inducing structural and functional neural changes in targeted areas of the brain. Through its novel Neuroplastogen Platform, Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and rapidly advancing through preclinical and clinical development to bring patients FDA-approved, take-home medicines that are intended to serve several unmet needs and enhance the psychiatric treatment paradigm for patients and providers.

VANCOUVER, British Columbia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company announces that it has completed its previously announced name change to Algernon Health Inc. The Company’s common shares will begin trading under the new name on the CSE at market-open on Monday, October 20, 2025. The common shares will trade under the new name with a new CUSIP number, but the stock symbol will remain the same. In connection with the name change, the following new CUSIP (01559C106) and ISIN (CA01559C1068) numbers have been assigned to the common shares of the Company. No action is required to be taken by the shareholders with respect to the name change. This name changeover on the Company’s website, in its digital marketing and social media materials and links, and in its URL and company email addresses will be changed on a rolling basis over a short window of time, as files and platforms are updated and refreshed across various networks and platforms. The name change reflects the Company’s recent announcement that it will be focusing on the Alzheimer’s Disease (AD) diagnostic market with plans to establish specialized neuroimaging clinics across North America as its lead program. The clinics will feature the latest technology of U.S. FDA-cleared, optimized brain-specific Positron Emission Tomography (PET) scanning systems to detect amyloid plaques in patients, providing significantly lower radiation compared to standard PET/CT machines currently in operation globally. The PET scans are covered by Medicare, Medicaid, and private insurance. The Company recently announced that it had signed a definitive equipment order and financing agreement with Catalyst MedTech (“Catalyst”) for the provision of four Oncovision CareMiBrain™ brain-specific, Positron Emission Tomography (PET) scanner systems to be utilized in four planned Algernon neuroimaging medical clinics. This represents a non-dilutive deal value of over CDN $4 million and includes an agreement to acquire an additional six systems for the establishment of additional clinics, on an adjusted cost basis. “Our change in name is an important step in the execution of our new health care initiative to establish and operate dedicated neuroimaging clinics for the early-stage detection of Alzheimer’s disease,” said Christopher J. Moreau, CEO of Algernon Health. “It underscores our commitment as an evolving, consumer facing brand providing health care solutions to patients in need.” Algernon continues to be the parent company of a private subsidiary called Algernon NeuroScience that has been advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury recovery. The Company also owns a 20% equity position in Seyltx, a private U.S. based drug development company advancing a chronic cough drug called Ifenprodil. Christopher J. Moreau CEO Algernon Health Inc. 604.398.4175 ext 701 info@algernonpharmaceuticals.com investors@algernonpharmaceuticals.com www.algernonpharmaceuticals.com. About Algernon Health Algernon Health is a Canadian healthcare company focused on the provision of brain specific PET scanning services through a planned network of new clinics in North America for the early-stage detection of Alzheimer’s disease, as well as other forms of dementia, epilepsy, neuro-oncology, and movement disorders. Algernon is also the parent company of a private subsidiary called Algernon NeuroScience that has been advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury recovery. The Company also owns a 20% equity position in Seyltx, a private U.S. based drug development company advancing a chronic cough drug called Ifenprodil. Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law. Released October 15, 2025